Paxlo® is a generic version of Pfizer’s Paxlovid™ manufactured by Opsonin Pharma. Pfizer’s Paxlovid™ is the first US FDA-approved oral therapy for the covid-19 treatment. Paxlo contains Nirmatrelvir Inn 150 mg and Ritonavir USP 100 mg same as that of Paxlovid by Pfizer. Paxlo shows a remarkable reduction rate in the risk of hospitalization or death. The FDA has authorized the emergency use of PAXLOVID for the treatment of mild-to-moderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under a EUA. Paxlo also can be made available under EUA even if it’s not approved in your country. Paxlo is effective against all variants including Delta & Omicron.